the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and polycythemia vera must be excluded. The present case and others in the literature indicate that the ...

Incyte shares (NASDAQ:INCY) saw their price target increased by TD Cowen from $86.00 to $88.00, with the firm maintaining a ...

A panelist discusses how polycythemia vera (PV) impacts daily life and lifestyle management, including beneficial changes ...

If you have the JAK2 V617F mutation, are aged 18-74 years old, do not smoke, do not have any known autoimmune disease, and attend medical checks at UAB regularly, you may be eligible for our study!

panelist discusses how polycythemia vera (PV) treatment approaches include both therapeutic phlebotomy and medications like hydroxyurea or interferon to control blood counts, with treatment selection ...

Drugmaker Incyte Corp reported fourth-quarter revenue above Wall Street estimates on Monday, boosted by strong demand for its key blood-cancer drug Jakafi and skin-disorder treatment Opzelura.

Posting $162 million in fourth-quarter net sales, a 48% increase, and $508 million for the whole yeara 50% riseOpzelura ...

Incyte Corp (INCY) reports a 15% revenue increase for 2024, driven by robust sales of Jakafi and Opzelura, while maintaining ...

Rusfertide For The Treatment Of Patients With Polycythemia Vera I believe that the company has done well to achieve positive results with its partner Johnson & Johnson to develop the use of IL-23R ...